Finance

Beta
Lists
IMCR:NASDAQ
Immunocore Holdings PLC - ADR
$28.29
-1.63%
(-0.47) 1D
$28.29
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMCR...
Open
$28.76
High
$29.10
Low
$27.67
Mkt. cap
1.44B
Avg. vol.
388.06K
Volume
282.08K
52-wk high
$40.71
52-wk low
$27.56
EPS
-$0.56
Beta
0.74
Shares outstanding
50.87M
No. of employees
524
Open
$28.76
High
$29.10
Low
$27.67
Mkt. cap
1.44B
Avg. vol.
388.06K
Volume
282.08K
52-wk high
$40.71
52-wk low
$27.56
EPS
-$0.56
Beta
0.74
Shares outstanding
50.87M
No. of employees
524
Analyst outlook
Analyst Ratings
Based on 9 analysts giving stock ratings to IMCR in the past 3 months
Buy
Buy
6
Hold
3
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for IMCR in the last 3 months.
Highest
Current $28.29
$100.00 (+253.48%)
Average
$65.13 (+130.22%)
Lowest
$33.00 (+16.65%)
News stories
From sources across the web
Profile
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
About Immunocore Holdings PLC - ADR
CEOBahija Jallal
Employees524
Founded2008
Headquarters-
SectorBiotechnology
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.25 / -$0.26
+196.46%beat
Revenue / Est. (USD)
106.68M / 106.74M
-0.06%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
97.96M
103.69M
104.48M
106.68M
Cost of goods sold
70.05M
71.08M
81.52M
434.00K
Cost of revenue
70.05M
71.08M
81.52M
434.00K
Research and development expenses
-
-
-
61.11M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
42.79M
39.78M
42.64M
37.85M
Operating expense
42.79M
39.78M
22.92M
98.96M
Total operating expenses
112.84M
110.86M
104.44M
99.40M
Operating income
-14.88M
-7.17M
37.00K
7.28M
Other non operating income
4.69M
5.06M
-15.22M
-
EBT including unusual items
-9.69M
304.00K
-15.79M
13.27M
EBT excluding unusual items
-9.69M
304.00K
-15.79M
11.50M
Income tax expense
606.00K
481.00K
14.27M
301.00K
Effective tax rate
-6.25%
158.22%
-90.33%
2.27%
Other operating expenses
-
-
-19.73M
-
Net income
-10.30M
-177.00K
-30.06M
12.97M
Net profit margin
-10.51%
-0.17%
-28.77%
12.16%
Earnings per share
-0.20
-
-0.60
0.25
Interest and investment income
4.27M
4.12M
3.91M
3.42M
Interest expense
-3.04M
-3.04M
-3.05M
-3.05M
Net interest expenses
1.23M
1.08M
853.00K
367.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.10M
-6.37M
871.00K
8.23M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more